{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:48:50Z","timestamp":1777625330854,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1189412"],"award-info":[{"award-number":["OPP1189412"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.xphs.2022.11.021","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:11:20Z","timestamp":1669839080000},"page":"458-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-5352","authenticated-orcid":false,"given":"Nitya","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-9106","authenticated-orcid":false,"given":"Kaushal","family":"Jerajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5010-7223","authenticated-orcid":false,"given":"Ozan S.","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi R.","family":"Pullagurla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5844-5710","authenticated-orcid":false,"given":"Oluwadara","family":"Ogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Mapari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Brendle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil D.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Batwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Mahedvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Dogar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Shaligram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-1998","authenticated-orcid":false,"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10197","key":"10.1016\/j.xphs.2022.11.021_bib0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.xphs.2022.11.021_bib0002","first-page":"726","article-title":"Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries","volume":"81","author":"Drain","year":"2003","journal-title":"Bull World Health Organ"},{"issue":"17","key":"10.1016\/j.xphs.2022.11.021_bib0003","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.vaccine.2016.11.066","article-title":"Doses per vaccine vial container: an understated and underestimated driver of performance that needs more evidence","volume":"35","author":"Heaton","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.xphs.2022.11.021_bib0004","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/jps.20976","article-title":"Antimicrobial preservative use in parenteral products: past and present","volume":"96","author":"Meyer","year":"2007","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2022.11.021_bib0005","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.xphs.2017.02.007","article-title":"Correlating the effects of antimicrobial preservatives on conformational stability, aggregation propensity, and backbone flexibility of an IgG1 mAb","volume":"106","author":"Arora","year":"2017","journal-title":"J Pharm Sci"},{"issue":"22","key":"10.1016\/j.xphs.2022.11.021_bib0006","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.vaccine.2016.03.093","article-title":"Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers","volume":"34","author":"Lal","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2022.11.021_bib0007","article-title":"Interaction of aluminum-adjuvanted recombinant P[4]protein antigen with preservatives: Storage stability and backbone flexibility studies","author":"Sawant","year":"2021","journal-title":"J Pharm Sci"},{"issue":"Suppl 3:S3","key":"10.1016\/j.xphs.2022.11.021_bib0008","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vaccine.2006.05.119","article-title":"Chapter 11: HPV vaccines: commercial research & development","volume":"24","author":"Inglis","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2022.11.021_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejpb.2019.05.027","article-title":"Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal","volume":"141","author":"Chen","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2022.11.021_bib0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jpha.2020.08.007","article-title":"Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal","volume":"11","author":"Huang","year":"2021","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.xphs.2022.11.021_bib0011","unstructured":"Bryan J, Brownlow M, Shi L, Casimiro D, McClements W, Meyer B, Hu B. Papillomavirus vaccine compositions. US 7,709,010 B2. May 4, 2010."},{"key":"10.1016\/j.xphs.2022.11.021_bib0012","first-page":"1","article-title":"Methylparaben as a preservative in the development of a multi-dose HPV-2 vaccine","author":"Miao","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.xphs.2022.11.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2022.07.019","article-title":"Analytical and preformulation characterization studies of human papillomavirus virus-like particles to enable quadrivalent multi-dose vaccine formulation development","author":"Jerajani","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.11.021_bib0014","unstructured":"Jerajani K, Wan Y, Kumru OS, Pullagurla SR, Kumar P, Sharma N, Ogun O, Mapari S, Brendle SA, Christensen ND, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Joshi SB, Volkin DB. Multi-dose formulation development for a quadrivalent human papillomavirus virus-like particle-based vaccine: Part I- screening of preservative combinations (submitted)."},{"issue":"1","key":"10.1016\/j.xphs.2022.11.021_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/viro.1996.0466","article-title":"Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies","volume":"223","author":"Christensen","year":"1996","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.xphs.2022.11.021_bib0016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/viro.1996.0554","article-title":"Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6","volume":"224","author":"Christensen","year":"1996","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.xphs.2022.11.021_bib0017","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.virol.2006.12.002","article-title":"Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles","volume":"361","author":"Culp","year":"2007","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.xphs.2022.11.021_bib0018","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/jps.20377","article-title":"Stabilization of human papillomavirus virus-like particles by non-ionic surfactants","volume":"94","author":"Shi","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.11.021_bib0019","series-title":"GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) [package insert]","year":"2020"},{"issue":"12","key":"10.1016\/j.xphs.2022.11.021_bib0020","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1021\/bi052132g","article-title":"Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist","volume":"45","author":"Roy","year":"2006","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.xphs.2022.11.021_bib0021","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s11095-015-1697-z","article-title":"Interactions between peptide and preservatives: effects on peptide self-interactions and antimicrobial efficiency in aqueous multi-dose formulations","volume":"32","author":"Heljo","year":"2015","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.11.021_bib0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0378-5173(96)04577-2","article-title":"Aggregation of recombinant human growth hormone induced by phenolic compounds","volume":"140","author":"Maa","year":"1996","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2022.11.021_bib0023","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.xphs.2020.11.033","article-title":"Mechanism of thimerosal-induced structural destabilization of a recombinant rotavirus P[4]protein antigen formulated as a multi-dose vaccine","volume":"110","author":"Kaur","year":"2021","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.11.021_bib0024","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1039\/B815978E","article-title":"Interaction of thimerosal with proteins\u2014ethylmercury adduct formation of human serum albumin and \u03b2-lactoglobulin A","volume":"1","author":"Tr\u00fcmpler","year":"2009","journal-title":"Metallomics"},{"key":"10.1016\/j.xphs.2022.11.021_bib0025","unstructured":"Evans K, Yin H. Preservative-containing virus formulations. US 2007\/0148765 A1. June 28, 2007. 2007."},{"key":"10.1016\/j.xphs.2022.11.021_bib0026","unstructured":"Elder DP, Crowley PJ. Antimicrobial preservatives part one: choosing a preservative system. Available from: https:\/\/www.americanpharmaceuticalreview.com\/Featured-Articles\/38886-Antimicrobial-Preservatives-Part-One-Choosing-a-Preservative-System\/. Accessed June 05, 2022."},{"issue":"6","key":"10.1016\/j.xphs.2022.11.021_bib0027","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s11094-019-02038-4","article-title":"Modern preservatives of microbiological stability","volume":"53","author":"Anurova","year":"2019","journal-title":"Pharm Chem J"},{"issue":"1","key":"10.1016\/j.xphs.2022.11.021_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijfoodmicro.2012.12.028","article-title":"Biocide tolerance in bacteria","volume":"162","author":"Ortega Morente","year":"2013","journal-title":"Int J Food Microbiol"},{"key":"10.1016\/j.xphs.2022.11.021_bib0029","unstructured":"Ng AS, Mancinelli RJ, Hennessey JP. Preservatives for vaccines. US 6,790,445 B1. Sep. 14. 2004."},{"key":"10.1016\/j.xphs.2022.11.021_bib0030","series-title":"Handbook of Pharmaceutical Excipients","author":"Gable","year":"2017"},{"issue":"9","key":"10.1016\/j.xphs.2022.11.021_bib0031","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0264-410X(94)90296-8","article-title":"Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine","volume":"12","author":"Sawyer","year":"1994","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.xphs.2022.11.021_bib0032","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1016\/j.vaccine.2011.05.074","article-title":"Preservative of choice for Prev(e)nar 13\u2122 in a multi-dose formulation","volume":"29","author":"Khandke","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.xphs.2022.11.021_bib0033","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.xphs.2018.05.021","article-title":"Protein-excipient interactions evaluated via nuclear magnetic resonance studies in polysorbate-based multidose protein formulations: influence on antimicrobial efficacy and potential study approach","volume":"107","author":"Torosantucci","year":"2018","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.11.021_bib0034","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"npj Vaccines"},{"issue":"7","key":"10.1016\/j.xphs.2022.11.021_bib0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jps.3030480707","article-title":"The kinetics of degradation of chlorobutanol","volume":"48","author":"Nair","year":"1959","journal-title":"J Am Pharm Assoc Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.xphs.2022.11.021_bib0036","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.xphs.2022.11.021_bib0037","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nbt0710-671","article-title":"Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India","volume":"28","author":"Padmanabhan","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.xphs.2022.11.021_bib0038","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/jps.20696","article-title":"Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)","volume":"95","author":"Mach","year":"2006","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2022.11.021_bib0039","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.nano.2012.01.007","article-title":"Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles","volume":"8","author":"Zhao","year":"2012","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"10.1016\/j.xphs.2022.11.021_bib0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-9-52","article-title":"Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity","volume":"9","author":"Zhao","year":"2012","journal-title":"Virol J"},{"issue":"31","key":"10.1016\/j.xphs.2022.11.021_bib0041","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1016\/j.vaccine.2010.05.007","article-title":"Preformulation studies\u2013the next advance in aluminum adjuvant-containing vaccines","volume":"28","author":"Hem","year":"2010","journal-title":"Vaccine"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:24Z","timestamp":1777420824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922005330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0022354922005330"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.11.021","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}